PIK3CA

Based on the results of the SANDPIPER study in advanced, PIK3CA-mutated breast cancer, Genentech has decided not to advance development of the PI3 kinase inhibitor taselisib.

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

Originally published Dec. 12. SAN ANTONIO, TEX. – Fifteen years after it came on the market, Herceptin is still the poster child for personalized medicine, and when combined with chemotherapy it's still the standard of care for HER2-positive breast cancer.

By Ben Butkus
German molecular diagnostic services company Inostics is currently beta-testing its first assay kits featuring its BEAMing digital PCR technology, company officials said recently.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

Product Watch

Premium

Life Tech's Ion OneTouch system; Transgenomic's Surveyor Scan BRAF and PIK3CA mutation-detection kits.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.